Insiders are buying PayPal and these 3 other struggling stocks. Should you?

Posted: 23 February 2022 3:09 pm
GreenBidOfferInFinancialStockMarket_GettyImages_1800x1000 (1)

Insiders can be wrong, but it’s generally a good sign when they buy shares as prices fall, suggesting any problems are temporary.

PayPal’s stock has been in a free fall since July 2021, wiping out two years of gains. At the beginning of February this year, the stock dropped even more dramatically. Three PayPal insiders used this opportunity to buy shares.
When insiders go on a buying spree, typically they’re confident the stock will be worth more in the future. Should you follow their lead?
We found four companies where insiders have been buying since the beginning of the year. This could give you a glimpse of where to look for your next opportunity.

1. PayPal

Three PayPal (PYPL) executives bought 20,000 shares worth around $2.5 million at an average price of $122.47. As of mid-February, the price is trading closer to $100, meaning you could get a better entry price.
Company executives aren’t the only ones buying the stock. PayPal has been consistently buying back shares. It bought 15.4 million shares in the fourth quarter for $3.4 billion. The company will likely keep buying shares for the same amount this year.
Most Refinitiv and TipRanks analysts reiterated their price targets for the next 12 months, with most making a lower projection. However, the average analyst price target for PayPal stands at $185, which is almost 80% higher than current prices.

2. Biodesix

Three Biodesix (BDSX) executives bought 2,600,000 shares worth around $11.3 million with an average price of $4.35. This is the highest value that insiders purchased so far this year.
Biodesix is a US diagnostic company focusing on lung disease. The company offers several products that include COVID tests, and blood panels to help diagnose lung cancer.
The company trades at around $3, a drop of almost 90% from its peak at $32 in early 2021. Morgan Stanley has a price target of $11 for the next 12 months.

3. Nextera Energy

Four insiders bought around 74,000 shares of Nextera Energy (NEE) worth approximately $5.7 million at an average price of $76.60. This is the second-largest insider purchase this year in terms of overall share value.
Nextera Energy is a holding company focusing on electric power and energy infrastructure in North America. One of its subsidiaries generates renewable energy from the wind and sun.
The company trades at a 20% discount from its peak at the beginning of the year. Most analysts have a buy rating on the stock with a price target of $91, which is 23% higher than the current price.

4. Cincor Pharma

Five Cincor Pharma (CINC) insiders bought around 342,000 shares at an average price of $16, which makes this transaction worth $5.4 million.
Cincor Pharma is a clinical-stage biotech company focused on treating hypertension and other cardiorenal diseases. Interestingly, it went public in January this year at an IPO price of $16, the same price the insiders scooped up the shares.
Since its IPO, the stock is up 56% to $25 per share, making it one of the best bets in companies where insiders bought shares this year.

Don’t take insider transactions for granted

Insiders can be wrong. This is only a guideline to help you find companies to invest in. Do your own due diligence before making financial decisions.
Kliment Dukovski doesn’t own shares of the companies mentioned in the article as of the publishing date.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site